May 4, 2001
Statement from Guidant Corporation Regarding Heart Failure Trial Press Release

Indianapolis, IN and St. Paul, MN - Late this afternoon, various news organizations quoted a U.S. Food and Drug Administration (FDA) spokesperson who commented on Guidant's May 2 release announcing the results of its CONTAK CD(tm) clinical trial.

Guidant has received no notification from the FDA regarding any issues related to the press release.

The company believes it is in full compliance with all legal and regulatory guidelines regarding public communication and disclosure of material information related to medical devices pending FDA approval.

Guidant is contacting the FDA regarding their spokesperson's comments.

A global leader in the medical technology industry, Guidant Corporation provides innovative, minimally invasive and cost-effective products and services for the treatment of cardiovascular and vascular disease.